Navigation Links
SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
Date:8/7/2009

BOTHELL, Wash., Aug. 7 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (NYSE Amex: DDD) today reported financial results for the three and six months ended June 30, 2009.

Dr. Bruce Morra, SCOLR Pharma's President and CEO, said, "We continue to advance discussions with a number of potential partners for our 12-hour controlled release ibuprofen. These potential partners have been committing resources to due diligence and preliminary negotiations of license terms. In the nutraceutical arena, we are working with companies interested in commercializing products we have developed for growing segments of this field in both the US and international markets. We continue to work with our investment bankers on potential strategic transactions, including mergers and other business combinations that could yield opportunities to increase shareholder value and provide additional resources for us to develop our Controlled Delivery Technology (CDT(R)) platforms. However, we are faced with a difficult marketplace and many specialty pharmaceutical companies competing for alliances with the more established pharmaceutical and consumer product companies. Our operating strategy is to preserve our capital by limiting clinical and development expenses to our ibuprofen and pseudoephedrine lead products while also supporting our existing alliances. We have made significant reductions to our operating expenses so far this year and are continuing to evaluate additional areas to further minimize our burn rate."

Total revenues, which consist of royalty revenue from our collaboration agreements, decreased 17%, or $48,782 to $230,789 for the three months ended June 30, 2009, compared to $279,571 for the same period in 2008. This decrease is primarily due to lower royalty income from our relationship with Perrigo.

Royalt
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
2. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
3. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
4. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
5. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
6. ULURU Discussions to Acquire York Pharma, plc Are Currently Terminated
7. CutisPharma, Inc. Receives Verified Accreditation for Wholesale Distributors from the National Association of Boards of Pharmacy for Woburn Facility
8. Strativas Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA
9. Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis
10. Sinobiopharma, Inc. Appoints New Director of Marketing
11. Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Earlier this month, a report was created by ... Air Force on the performance of vehicles using an ... of fuel made from mustard seeds, offered great potential ... Eco friendly future. In fact, every branch of the ... of foreign oil over the next few years. They ...
(Date:8/27/2014)... Austin, TX (PRWEB) August 27, 2014 ... $6 million in Series B funding and secured Otter ... and investment capital will accelerate commercialization of GGI’s Agriplier™ ... multiple crop types. , “Since our first meeting, ... commitment to the biological product space,” said Alan Sobba, ...
(Date:8/27/2014)... is how plants survive impact by the huge ... while using this energy for photosynthesis. The hypothesis ... blades quickly dissipate the energy throughout the entire ... DTU Physics have now managed to successfully ,film, ... contain light-absorbing proteins which play a role in ...
(Date:8/27/2014)... MADISON, N.J. , Aug. 27, 2014 /PRNewswire/ ... significant potential to help physicians better identify early-stage ... progression and disability, according to a new study ... from Quest Diagnostics (NYSE: DGX ) ... of the 14-3-3eta protein outperformed conventional antibody-serum testing, ...
Breaking Biology Technology:Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3DTU researchers film protein quake for the first time 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4
... Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ) today ... 30, 2008., Total revenues in the second ... million in the second quarter of 2007, and ... agreement with,Siegfried Ltd and $0.6 million in patent ...
... Aug. 5 /PRNewswire-FirstCall/ - Atrium Innovations Inc.,(TSX: ATB), ... and professionally endorsed products for the health and,nutrition ... Officer, Mr. Pierre Fitzgibbon, will present a company ... Growth Conference on,Tuesday, August 12, 2008 at 11 ...
... Ltd. to Support Partnership, Comprehensive service will ... implementation of cognitive testing in clinical trials, BETHESDA, ... United BioSource Corporation (UBC) and CogState Ltd. enter into ... in,clinical trials., -- UBC has made a direct ...
Cached Biology Technology:Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights 2Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights 3Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights 4Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights 5Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights 6Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights 7Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights 8Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights 9United BioSource Corporation and CogState Ltd. Form Strategic Partnership to Support Cognitive Assessment in Clinical Research 2United BioSource Corporation and CogState Ltd. Form Strategic Partnership to Support Cognitive Assessment in Clinical Research 3United BioSource Corporation and CogState Ltd. Form Strategic Partnership to Support Cognitive Assessment in Clinical Research 4
(Date:8/27/2014)... is entering what is described by the Volunteer Wildfire ... The Eastern Cape provincial government warned residents in certain ... winds and veld fires. A high veld fire ... along the coast in the Great Kei and Mnquma ... and during thunderstorms. The thunderstorms bring lightning strikes ...
(Date:8/27/2014)... as giant, frightening beasts. But every creature is a ... slab containing fossils of 24 very young dinosaurs and ... hatchlings overseen by a caretaker, according to a new ... P. Hedrick and Peter Dodson led the work, collaborating ... where the specimen is held. Hedrick is a doctoral ...
(Date:8/27/2014)... exists as five strains, none of which have approved ... Sudan ebolavirus (SUDV). Although not the strain currently devastating ... recently as 2012. In a new study appearing in ... report a possible therapy that could someday help treat ... Jonathan Lai and colleagues explain that about 50-90 percent ...
Breaking Biology News(10 mins):Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 2Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 3Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks 2
... Washington, D.C.Recent climate modeling has shown that ... atmosphere would give the Earth a wetter climate ... Global Ecology scientists Long Cao and Ken Caldeira ... wetter when atmospheric carbon dioxide (CO2) concentrations are ...
... (March 24, 2011) Researchers with the Los Angeles ... of the multi-drug resistant pathogen, carbapenem-resistant Klebsiella pneumoniae (CRKP) ... compared to general acute care hospitals across the county. ... thought to be contained to East Coast facilities and ...
... and brings new dimensions into teaching and research. ... have in collaboration with the Finnish company Multitouch Ltd ... method is a combination of two technologies: web-based virtual ... is an entirely new way of performing microscopy: by ...
Cached Biology News:Cutting carbon dioxide helps prevent drying 2Drug-resistant pathogen found in large numbers in LA County 2Big size multitouch display turned into a microscope 2